1-5 of 5
Kejal Parikh, BSPharm, MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Outcomes for Maintenance Treatment Sequencing after Receiving Lenalidomide, Bortezomib, and Dexamethasone Induction in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Followed By Autologous Stem Cell Transplant (ASCT)

Rafael Fonseca, MD, Kejal Parikh, BSPharm, MS, Brian Ung, PharmD, Quanhong Ni, MS, Safiya Abouzaid, MPH, PharmD, Amit Agarwal, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3463.
https://doi.org/10.1182/blood.V130.Suppl_1.3463.3463
Published: 2017
Journal Articles

Racial Disparities in Treatment Patterns and Outcomes Among Patients with Multiple Myeloma: A SEER-Medicare Analysis

Sikander Ailawadhi, Kejal Parikh, BSPharm, MS, Zhou Zhou, MS, Wenxi Tang, MS, Zoe Clancy, MS, PharmD, Claudia Cheung, MS, Zheng-Yi Zhou, PhD, Jipan Xie, MD PhD, Safiya Abouzaid, MPH, PharmD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3426.
https://doi.org/10.1182/blood.V130.Suppl_1.3426.3426
Published: 2017
Journal Articles

Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma Post Autologous Stem Cell Transplant: A Comparison of Real-World Treatment Outcomes and Costs

Parameswaran Hari, MD MRCP, MS, Brian Ung, PharmD, Safiya Abouzaid, MPH, PharmD, Quanhong Ni, MS, Kejal Parikh, BSPharm, MS, Amit Agarwal, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2189.
https://doi.org/10.1182/blood.V130.Suppl_1.2189.2189
Published: 2017
Journal Articles

Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database

Ajai Chari, MD, Brian Ung, PharmD, Safiya Abouzaid, MPH, PharmD, Quanhong Ni, MS, Kejal Parikh, BSPharm, MS, Amit Agarwal, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2190.
https://doi.org/10.1182/blood.V130.Suppl_1.2190.2190
Published: 2017
Journal Articles

Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint

Aaron Seth Rosenberg, MD, Thierry Facon, MD, Safiya Abouzaid, MPH, PharmD, Shankar Srinivasan, PhD, Weiyuan Chung, Kejal Parikh, BSPharm, MS, Joseph Tuscano, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3113.
https://doi.org/10.1182/blood.V130.Suppl_1.3113.3113
Published: 2017